ArticleDrug design, development and therapy2026
Risk Factors for Amisulpride-Associated Hyperprolactinemia: Gender-Specific Plasma Concentration Cutoffs Derived from ROC Analysis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate independent risk factors for amisulpride-induced hyperprolactinemia (HPRL), establish gender-stratified diagnostic cutoff values for HPRL, and determine amisulpride plasma concentration cutoff values for different genders, thereby providing a basis for personalized medication. Patients and Methods: This retrospective study included 209 patients treated with amisulpride. Significant univariate variables were entered into multivariable linear regression to identify independent predictors. We used receiver operating characteristic (ROC) curve analysis to determine the overall prolactin cutoff of 28 ng/mL for identifying HPRL. Sex-stratified ROC analyses were further conducted to establish gender-specific optimal amisulpride plasma concentration thresholds. Results: Daily amisulpride dose was positively correlated with plasma drug concentration (p < 0.001); multivariable analysis identified sex, plasma amisulpride concentration, and concomitant idebenone or lorazepam use as independent risk factors for amisulpride-induced prolactin elevation (p < 0.05). ROC analysis identified a screening cutoff value of 28 ng/mL for elevated prolactin levels in the overall population. Plasma amisulpride concentration cutoffs were higher in women (317.8 ng/mL) than in men (294.2 ng/mL), suggesting greater tolerance to higher plasma concentrations among women and confirming significant sex differences in susceptibility to amisulpride-induced prolactin elevation. Conclusion: Clinically, 28 ng/mL can be adopted as the screening cutoff value for elevated prolactin levels in patients treated with amisulpride, we advocate for sex-dependent plasma concentration management for personalized therapeutic drug monitoring to effectively prevent and control amisulpride-associated HPRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.